Mabpharm Limited (HK:2181)
:2181
Top Page
Mabpharm Limited
(2181)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$0.51
▲(1.40% Upside)
Action:UpgradedDate:12/03/25
Mabpharm Limited faces significant financial challenges, with high leverage and negative cash flows being the most critical factors. Technical indicators suggest a bearish trend, and the valuation is unattractive due to ongoing losses. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Revenue Growth
A nearly 200% year-over-year revenue increase indicates meaningful top-line traction and growing market acceptance. Sustained revenue expansion provides operating leverage potential, funding runway for R&D and commercialization efforts, and a stronger negotiating position with partners over the coming months.
Negative Factors
High Leverage
Substantial leverage (debt/equity 3.50) and a low equity ratio constrain financial flexibility and increase refinancing and covenant risk. In a capital-intensive biotech model, high debt amplifies vulnerability to cash shortfalls and limits ability to fund trials or scale operations without costly external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A nearly 200% year-over-year revenue increase indicates meaningful top-line traction and growing market acceptance. Sustained revenue expansion provides operating leverage potential, funding runway for R&D and commercialization efforts, and a stronger negotiating position with partners over the coming months.
Read all positive factors
Mabpharm Limited (2181) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.06B
Dividend YieldN/A
Average Volume (3M)354.33K
Price to Earnings (P/E)33.3
Beta (1Y)0.87
Revenue Growth178.36%
EPS Growth86.74%
CountryHK
Employees315
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.01
Shares Outstanding4,124,080,000
10 Day Avg. Volume54,400
30 Day Avg. Volume354,333
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)12.19
Price to Sales (P/S)4.20
P/FCF Ratio-17.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mabpharm Limited Business Overview & Revenue Model
Company Description
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China. Its products under the Phase III clinical trial include...
How the Company Makes Money
Mabpharm Limited generates revenue primarily through the development and commercialization of its proprietary biologic drugs. The company's revenue model includes income from product sales once therapies receive regulatory approval and are launche...
Mabpharm Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
35
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 423.93M | 258.23M | 87.16M | 55.92M | 82.88M | 0.00 |
| Gross Profit | 366.28M | 219.39M | 75.24M | 40.54M | 66.11M | 0.00 |
| EBITDA | 28.72M | -67.81M | -139.08M | -152.08M | -245.46M | -169.93M |
| Net Income | -27.48M | -127.95M | -209.36M | -210.62M | -291.74M | -188.57M |
Balance Sheet | ||||||
| Total Assets | 1.07B | 1.02B | 1.03B | 917.52M | 899.90M | 1.16B |
| Cash, Cash Equivalents and Short-Term Investments | 94.16M | 89.34M | 173.34M | 48.61M | 81.56M | 484.85M |
| Total Debt | 305.01M | 293.09M | 260.07M | 126.34M | 46.43M | 40.35M |
| Total Liabilities | 968.98M | 927.28M | 829.92M | 516.58M | 297.92M | 281.55M |
| Stockholders Equity | 98.86M | 88.93M | 205.06M | 400.94M | 601.98M | 881.49M |
Cash Flow | ||||||
| Free Cash Flow | 53.59M | -63.58M | 38.35M | -182.01M | -348.14M | -344.47M |
| Operating Cash Flow | 103.11M | -4.10M | 57.39M | -56.88M | -199.47M | -147.23M |
| Investing Cash Flow | -110.67M | -98.20M | -3.50M | -104.95M | -179.42M | 156.00M |
| Financing Cash Flow | 27.63M | 18.28M | 85.60M | 112.26M | -17.78M | -80.48M |
Mabpharm Limited Technical Analysis
Negative
0.50
Price Trends
0.51
Negative
0.52
Negative
0.57
Negative
Market Momentum
<0.01
Positive
46.88
Neutral
21.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2181, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.51, and below the 200-day MA of 0.57, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.88 is Neutral, neither overbought nor oversold. The STOCH value of 21.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2181.
Mabpharm Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | 0.99% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$2.06B | 33.28 | 43.89% | ― | 178.36% | 86.74% | |
45 Neutral | HK$2.42B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
44 Neutral | HK$1.01B | -18.55 | -15.19% | ― | ― | 22.65% | |
43 Neutral | HK$1.68B | -6.43 | 293.08% | ― | ― | 27.90% | |
41 Neutral | HK$3.37B | -9.15 | -26.73% | ― | 49.64% | 59.58% |
* Healthcare Sector Average
HK:2181
Mabpharm Limited
0.50
0.05
11.11%
HK:6996
Antengene Corporation Limited
5.32
3.07
136.44%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.41
214.47%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
4.13
2.27
122.04%
HK:3681
SinoMab Bioscience Ltd.
1.76
0.59
50.43%
HK:6978
Immunotech Biopharm Ltd
2.72
-0.40
-12.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.